Anti-PD-1/PD-L1 immunotherapy disrupts the PD-1/PD-L1 signaling pathway [134], which restores T cell activity, enhances anti-tumor immunity, and ultimately contributes to the elimination of cancer cells [135,136]. The gene discussed is CD274; the disease is neoplasm.